Partner Or Go It Alone? TG Therapeutics Ponders EU Plans For Briumvi
MS Drug Approved By European Commission
TG Therapeutics has successfully launched Briumvi on its own in the US, despite fierce competition from established same-class MS drugs Ocrevus and Kesimpta, but is still weighing up the pros and cons of partnering for the European market.
